Almost there with 990! It's amazing the positive shareholder/investor/follower response which has been pouring into the new Regen Biopharma twitter page in just 3 days since its launch! The market is very receptive to this and likes this because it shows that the company is now going to be more active with company and shareholder updates besides press releases and SEC filings. It's very good to have an active social media presence to create more public awareness of the things the company will be working on and a platform to make public announcements and provide shareholder support! Best wishes everyone for 2022!
https://twitter.com/TheRegenBio

Over 900 Followers now on the new Regen BioPharma Twitter account page in only 2 days! This is outstanding and shows a lot of interest by investors in the company and the stock! Best wishes everyone for 2022!
https://twitter.com/TheRegenBio

$RGBP Outstanding Shares Update 01/01/2022...
No changes from 12/01/2021 to 01/01/2022! Great news!
Best wishes everyone for 2022!

January 1, 2022 Outstanding Shares...


December 1, 2021 Outstanding Shares...

I agree 100%! Best wishes for 2022!

Blessings and best wishes,
LoveAndLight

Yes! This deal with the Canary acquisition and Cornell connection will be huge if it all goes through with the $50 million in funding for it. This will be a major milestone for Regen BioPharma. It would be the biggest deal yet and would have a major impact on the stock. Perhaps more so than the licensing deals with Oncology Pharma, and look what those did for the stock! Happy New Year 2022!

Blessings and best wishes,
LoveAndLight

CEO Dr. Koos Message to Shareholders 12-30-2021
https://www.prnewswire.com/news-releases/regen-biopharma-inc-message-to-the-shareholders-from-the-chairman-and-chief-executive-officer-301452028.html

REGEN BIOPHARMA, INC.: MESSAGE TO THE SHAREHOLDERS FROM THE CHAIRMAN AND CHIEF EXECUTIVE OFFICER

News provided by
Regen BioPharma, Inc.
Dec 30, 2021, 15:41 ET

SAN DIEGO, Dec. 30, 2021 /PRNewswire/ -- Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP):

First of all I would like to wish all our shareholders a happy holiday season. It has been a long year with many challenges and many successes.

When I returned to Regen on March 23, 2021 in order to serve as Chairman and Chief Executive Officer I found myself at the helm of a company on the verge of collapse. We were behind in bills, at risk of losing patent protection on valuable IP, and delinquent in our SEC filing obligations. Worse of all we were being sued by Chemdiv-our Contract Research Organization- in a complaint seeking damages of $1,200,000 which also threatened our ownership rights to valuable intellectual property.

As the year progressed we faced the challenges that lay before us and conquered them. Regen has revived numerous valuable existing IP which had been deemed abandoned by the United States Patent and Trademark Office, settled its lawsuit with Chemdiv, been issued several new patents, entered into two non-related party licensing agreements and became current in its SEC filing obligations eliminating the risk that the public trading market for both the common and Series A preferred shares would disappear.

Becoming current in our SEC reporting obligations after such a long delinquency was a significant achievement. Recent amendments to SEC Rule 15c2-11 threatened the public trading status of delinquent issuers. Had I not been able to get the Company current there was a real possibility that our shareholders wouldn't be able to trade their shares and the Company's ability to raise capital would be adversely effected.

I have received numerous texts, emails and phone calls regarding our restatement of our third quarter financials.

During the quarter ended June 30, 2021 the Company was paid $1,905,000 in cash and securities resulting from two licenses granted in April, 2021 to Oncology Pharma, Inc. ("ONPH").

Pursuant to the terms and conditions of the licenses granted ONPH became obligated to:
(a) Pay nonrefundable fees of $55,000 and fifty thousand common shares of ONPH no later than April 20, 2021

(b) Pay royalties equal to five percent (5%) of the Net Sales (as Net Sales are defined in the Agreement) of any Licensed Products in a quarter.

Accounting for Revenues from contracts with customers and licensees is governed by Accounting Standard Codification 606 ("ASC 606") issued by the Financial Accounting Standards Board ("FASB").

ASC 606 requires that revenue be recognized as performance obligations are fulfilled. In considering the accounting for revenue generated by the licenses, the Company initially determined that the nonrefundable fees paid were consideration solely for entering into the agreement and thus should be recognized within the quarter in which they were paid.

A subsequent examination in conjunction with the Company's public accountant led us to reconsider this accounting treatment and we determined that – in order to be compliant with ASC 606- the revenue generated by the payment to the Company of the nonrefundable fees would need to be recognized over the term of the licenses. We arrived at the conclusion that entering into the agreement did not adequately meet the criteria of being "distinct within the context of the contract" from the obligation of granting the license over the term of the contract. None of the abovementioned changes the fact that $1,905,000 in cash and securities was paid to the Company during the quarter ended June 30, 2021 and this payment was nonrefundable.

Looking into the New Year I will work diligently towards the goal of entering into additional co-development projects and collaborations that I believe will benefit Regen's shareholders and I expect to identify a contract research organization that will help us move the Company's intellectual propriety towards clinical trials.

During this past year I haven't taken a dime in salary from Regen. The reason for this is because I see our company for all its potential and possibilities and I'm betting on what we have and what we can achieve.

Sincerely,
David R. Koos
Chairman & CEO
Regen BioPharma Inc.

If anyone hasn't read this new article and report on Regen BioPharma... I suggest you do! I concur with OTCShotCaller! It's excellent! Best wishes everyone.
https://pennystocks.today/rgbp-stock-the-biotech-stock-to-look-out-for-in-2022/

Blessings and best wishes,
LoveAndLight

Great stuff! Thanks!

Blessings and best wishes,
LoveAndLight

I hope Dr. Koos files a counter lawsuit for damages against the Pomerantz law firm! They're a bunch of criminals working for the mafia hedge funds who file frivolous and bogus claims against companies just to manipulate and drive the stock price down. That's exactly what occurred today! They are the ones committing illegal activities and fraud!

The company filed an 8-K and a 10-Q/A to simply correct and report an accounting error. That's securities fraud??? Total BS! The company did the right thing by correcting what was reported in the 10-Q.

I would think Dr. Koos was probably being advised by his own legal counsel today on things that he can do to counter this. I hope he gets after them with retribution for pulling this crap! Even though it's not probably the way he'd like to be spending his time. But I think he needs to defend the company and send a clear message that this is unacceptable. Not only for the benefit of shareholders, but also for the integrity of the company in the eyes of business associates. He needs to do damage control on this and hold some people accountable with a counter suit investigation!

I hope he sues the shit out of these guys and perhaps even files for criminal charges after an indictment for investigative discovery to find out which hedge funds were behind all of this along with that law firm being in collusion! It is very evident that they intentionally caused damage to the company and the stock. I call bullshit! The people who were involved in this smear campaign to maliciously manipulate and drive the stock price down so the hedge funds could profit more and cover their short positions at a lower price need to go do some jail time! Hehe! I hope these shysters do! Screw them!

And we as the honest and loyal long retail investors and innocent bystanders need to support the company and our CEO over this!

Best regards everyone,
LoveAndLight

Thank you! Yes! So many great things being worked on that this company can help provide and can help change the landscape of future cancer therapies! God Bless!

Blessings and best wishes,
LoveAndLight

I agree! This is pretty much a done deal which Dr. Koos has laid out for us which is being worked on. Just have to wait for the big announcement of who is going to be involved with helping to supply the capital resources for Regen BioPharma once the details of whatever the deal is going to be are finalized. Anticipation... Hehe!

Blessings and best wishes,
LoveAndLight

That's a great link and list of all the Regen BioPharma medical professional connections! Thanks for sharing that!

Blessings and best wishes,
LoveAndLight

That's a great press release from 2015! It describes all the important attributes of NR2F6 that can be applied to anti-tumor cancer therapeutics today, which the company can now move forward on in its drug development with clinical trials. It's timeless in its implications for the future in curing cancer. We just need a big financial partner now who can help make that happen! Thanks for sharing that! It's appreciated and good to see again.

Blessings and best wishes,
LoveAndLight

Yes sometimes it's hard to keep track of everything that's a part of all this. Even things from many years in the past are coming back into play here. But it's all pretty cool! Looking forward to it all coming together in a major way!

Blessings and best wishes,
LoveAndLight

Wow! That would be amazing! And yes now I remember that the Ichim doctors are siblings. Thanks for the reminder. It's been a while since I've heard any discussions about them. They are such an integral part of Regen BioPharma through their patents. Hope they become more of a major factor here at the corporate level in a larger company with a broader scope of an excellent scientific team.

Blessings and best wishes,
LoveAndLight

That's right... Yeah I stand corrected! Thank you for the reminder, I just forgot. Yes now I remember about the Ichim doctors being siblings. Quite a story of remarkable accomplishments they have made together! It's great that Dr. Koos made the business connection with them to have ties with Regen BioPharma.

Blessings and best wishes,
LoveAndLight

Actually I just found two of the patents that have been "granted" to Regen BioPharma which has Christine Victoria Ichim's name all over them as an inventor! There could be more.

Modulation of NR2F6 and methods and uses thereof
https://uspto.report/patent/grant/9,091,696#:~:text=regen%20biopharma

Wow! This one too...
Methods of screening compounds that can modulate NR2F6 by displacement of a reference ligand
https://uspto.report/patent/grant/10,088,485#:~:text=regen%20biopharma

Blessings and best wishes,
LoveAndLight

Yes, there is a very good possibility of that... She is married to Dr. Thomas Ichim, who is listed as an inventor along with Dr. Harry Lander and Dr. David Koos on many of Regen BioPharma's patents. And yes I believe they have a long history together of working on research and studies for the development of NR2F6 small molecule IP. She may even be listed as an inventor on some of the Regen BioPharma patents herself, but I can't remember for sure. But she definitely has done a lot of past research on the subject.

Blessings and best wishes,
LoveAndLight

Yes! I can appreciate that! Hehe! This a good company and stock to be invested in! It's good to be a part of it.

Blessings and best wishes,
LoveAndLight

Thank you! I just think no matter what happens here... It's going to be really good to be a part of!

Blessings and best wishes,
LoveAndLight

Everyone has their own timelines and reasons for retiring or for continuing to work. Again, no one knows what Dr. Koos's plans are for his purpose in life. There may still be some remarkable accomplishments that he would still like to be a part of and see through to completion. All we can do is speculate about it and I really don't see a need or a point in doing that. What will be, will be. And I don't think it will matter either way. It will still be a successful conclusion. Just be in it and along for the ride!

Blessings and best wishes,
LoveAndLight

Here is my opinion on this important subject... Dr. Koos is only in his mid 60s... That's still fairly young in the corporate world of CEOs. He could easily work for another 10 years or so as a CEO of Regen BioPharma if he feels he wants to take on that role and steer the ship for a while longer before he finally retires from the business. He's still fully capable of that. Perhaps he would still enjoy and desire doing the job and playing that role. But no one knows what his intentions are long term in that regard. Only he does and perhaps some people who are close around him. And it sure doesn't sound like he's getting the company ready to be sold anytime soon to me. And here is why...
The very first couple of lines in the PR just released this past Wednesday stated this:

This does not sound like a plan for the future which involves selling the company any time soon! It sounds to me like the company is going to be settling in for a while to build on it's own growth story with the development of its own technological successes in the biotech space. However, I do see that perhaps a huge Joint Venture/Partnership deal could happen with Eli Lilly or another big pharma which would be amazing for the company and shareholders in and of itself to help assist the company in driving the business forward in a more accelerated way. A perfect situation would be something along the lines of a 60/40 percent type of partnership arrangement where the company would keep a 60% majority ownership controlling interest, and whichever company that would take a 40% ownership position would be there to help fund the company for all its development projects. As a long term shareholder I would take that and welcome something like that in a heartbeat! Hehe!

Blessings and best wishes,
LoveAndLight

$RGBP Some Chart Technicals leading into the end of November...
Has everyone noticed that we are at a very firm "support" area right now just above the 200 day moving average that sits at .02? Some have suggested that we are still going to test dropping below that level again. And maybe I could be wrong, but I honestly don't think that is going to happen. Notice the blue line of all the prior support at this level in the past. Yes it did breach that support back at the end of October but it was only for a very brief period of 4 days before it made a very strong rebound from the .016s on 11/2 where it more than doubled in price to the .035s through 11/8! So the month of November started off very strongly. And now yes we've had a pull back to the low .02s again... But I firmly believe the month of November is going to close out with a very strong finish in the final 6 trading days! I think $RGBP will close out back above the 50DMA which currently sits at .026! Best wishes everyone!

That is one fantastic post! Great analysis falon! I totally overlooked that there is a timeline set to get this done within 90 days of the date of the LOI which is 1/26/2022. Great stuff! Thank you!

Blessings and best wishes,
LoveAndLight

$RGBP Closing Chart 11/16/2021...
Looks like Tuesday was a capitulation day in the current 6 day slide. The good news is the closing price was a tick above the opening price and formed a doji candle. This usually is a good sign as being the signal for a reversal. Also the low of the day held strong above the key support area of the 200 day moving average which in my opinion is the very bottom of this trading range. I believe Wednesday is going to be a good day for the stock in starting a turnaround. And by all rights... It should! Best wishes everyone.

Oh yes okay got ya! Sorry. Yes it's possible that assessment may remain undisclosed to the public market and we may never see it being released. The company may even have NDAs with individuals, companies and in this case a University who they may be sharing it with for various reasons. And yes I agree the third party assessment most likely played a big roll in the whole deal that was drawn up for the acquisition of Canary with Dr. Lander being involved and the agreement between the company and Cornell University with Dr. Shahin Rafii, his lab and staff to participate with Regen BioPharma's endeavors. The assessment for the NR2F6 IP and patents were being focused on in the assessment as well. So I'm sure all of this tied in with being one of the main reasons why the assessment was needed. The other factor that may have been in play here for getting the assessment done... was to evaluate the prospects for a JV/Partnership with Eli Lilly. So it's very obvious this was a very pivotal and essential thing which needed to be done for so many important business reasons.

Blessings and best wishes,
LoveAndLight

Well... I wouldn't say that Biotech Research Group is getting "fired" today... LOL! November 15, 2021 is just the end of the term agreed upon for completing the Scope of Work order for the IP assessment. Those guys don't get fired... They are a top of the line professional company who will do an outstanding job on the assessment, and if they say they will have it completed within a proposed time frame... I would say it's pretty much a guarantee! Hehe! And I'm sure they have probably already finished the assessment many days before the agreed deadline of today.

Blessings and best wishes,
LoveAndLight

There are corporate reasons for the acquisition of Canary I'm sure and it will all come together to make sense as it transpires. But if you want to know my take, I believe it was a means to get Dr. Harry Lander back on board with Regen and also a part of the deal to get Cornell University's participation with Regen. Anyway, bottom line is I trust Dr. Koos on this. He's a master at it!

Blessings and best wishes,
LoveAndLight

Loved your post! I agree with everything in it. Yes I also believe Dr. Koos has the $50M pre-arranged that he knows he will be receiving with another deal forthcoming with another entity to close the deal with Canary. Best case scenario to me would be some kind of a 60/40 joint venture shared partnership with Eli Lilly to help fund all these various business endeavors to develop the medical testing products, disease therapies and vaccines through the company's IP and patents and collaborations with Cornell University. I say 60/40 would be a nice split business arrangement because that way Regen BioPharma could retain and maintain control of majority interest in the company. I think we would really benefit a lot as common shareholders and it would be good to be able to maintain a stake in the company by continuing to own our shares should all of this go really big... verses a 100% buy out of the company to where we would be forced to give up our shares for a one time cash deal. Yes, I'm sure it would still be a good cash payout to receive for our shares, but I just think our shares may increase a lot more in value in the future than what we would receive in a 100% buy out. I'd really like to have a chance to see what the full potential may be from all this as a long term shareholder who can stay invested in it. Anyway, just some thoughts I have. I know a lot of people would like to see an outright 100% buy out which would be fine too if it happens. But I am just hoping for something exponentially much more than that!

Blessings and best wishes,
LoveAndLight

Wow! That's extraordinary! Thanks for sharing that! Yes it's amazing the work Dr. Rafii does. We are blessed that him and his lab and research team is coming onboard to be involved with helping Regen BioPharma!

Re-sharing the video link:

Blessings and best wishes,
LoveAndLight

Wow! Dr. Shahin Rafii from Cornell University is an amazing man. His world of expertise coming into Regen BioPharma's new acquisition plans is off the charts incredibly amazing! Everyone who is invested in Regen BioPharma should watch this video podcast interview with him!

Blessings and best wishes,
LoveAndLight

That is billiant! Re-sharing your post taken from the new 8-K...

https://www.sec.gov/ix?doc=/Archives/edgar/data/1589150/000160706221000512/rgbp111221form8k.htm

Blessings and best wishes,
LoveAndLight

Wow! That's incredible! What a find! Thanks for sharing that!

Blessings and best wishes,
LoveAndLight

Hey! How are you? Excellent post! Yes this is the best 8-K we could have hoped for right now! Confirmation that all the old convertible notes and debt have been settled and paid off with no longer any concerns for the issuance and sales of new shares and dilution of the common stock into the market.
So there is nothing that will hold $RGBP back now from the potential for massive gains! It is completely free to trade now without any barriers of resistance.
With each new positive development from here on out... The stock price will rise steadily in reaching new heights!

Blessings and best wishes,
LoveAndLight

Today's 8-K is Outstanding NEWS!!! Dilution is OVER!
Okay I'm just stopping by to make sure that there isn't anyone here who doesn't understand this!
The company has made things very clear in today's 8-K...
All the old convertible notes have been completely paid off in stock and cash. So there will no longer be any more conversions/dilution associated with those old debts!
The only promissory note that is left is the most recent loan that the company took out which has a remaining principle balance of $1,396,245, of which cash payments start in March of 2022 to start paying that loan off.
This remaining loan is NOT convertible unless the company were to default on its cash payment plan obligation.
And Dr. Koos will not let that happen!
Hope this helps to clear things up about anyone who may be confused about this.
Again... Today's 8-K filing news is outstanding! Let the $RGBP bull run begin! Hehe!

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001589150/000160706221000487/rgbp110521form8k.htm

Blessings and best wishes,
LoveAndLight

Yes but it hadn't been formally announced in an official 8-K SEC document filing. So now a lot more people are going to become aware of it. Also the timing of the 8-K is in line with the NR2F6 intellectual property associated patents valuation assessments due by November 15th. The timing of this is significant!

Blessings and best wishes,
LoveAndLight

Yes! This is truly amazing!

Blessings and best wishes,
LoveAndLight

$RGBP $RGBPP I would imagine this is one of the new patents that will be getting valuation assessed by November 15th, because it has to do with NR2F6 intellectual property! This is huge!
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001589150/000160706221000481/rgbp110321form8k.htm

Blessings and best wishes,
LoveAndLight

$RGBP How great is this?!!! Fabulous 8-K Patent Approval!
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001589150/000160706221000481/rgbp110321form8k.htm

Item 8.01 Other Events.

On October 12, 2021 the United States Patent and Trademark Office ( “USPTO”) issued Patent Number 11,141,471 B2 to Regen Biopharma, Inc. for “UNIVERSAL DONOR CHECKPOINT INHIBITOR SILENCED/GENE EDITED CORD BLOOD KILLER CELLS”

The invention encompasses compositions of matters, cells, and treatment protocols useful for induction of anticancer responses in a patient suffering from cancer. In one embodiment the invention provides the use of NR2F6 silencing or gene editing in cord blood cells possessing anti-tumor activity in order to induce potentiated killer cells suitable for therapeutic use. In one embodiment said allogeneic cord blood killer cells are administered to initiate a cascade of antitumor immune responses, with initially responses mediated by allogeneic killer cells, and followed by endogenous immune responses.

Blessings and best wishes,
LoveAndLight

Hi, No I don't believe the update to the OS is bad news. I think it is very good news that it is such a small amount compared to the previous two updates. And that would indicate that note conversions and the subsequent dilution is winding down, if not completely finished now. And besides that... The company is much more valuable than the current market cap of $71.6 million. That is ludicrous and the stock should be trading at much higher prices by all rights. But I don't see it staying down there much longer.

Blessings and best wishes,
LoveAndLight